Scientists from the University of California at San Francisco and Memorial Sloan-Kettering Cancer Center have used sequencing data from a single patient to identify mutations in the tuberous sclerosis complex 1 gene as a biomarker that can predict the response to the mTOR inhibitor Afinitor (everolimus, Novartis AG).